Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 301

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

The evolution of β‐cell dysfunction and insulin resistance in type 2 diabetes

Bergman, R. N., Finegood, D. T., Kahn, S. E.·2002·European Journal of Clinical Investigation
DOI 10.1046/j.1365-2362.32.s3.5.x
Open this paper in CoChat — free account

Abstract

Insulin resistance and β‐cell dysfunction have important roles in the pathogenesis and evolution of type 2 diabetes. The development of precise methods to measure these factors has helped us to define the relationship between them and evidence is reviewed that changes in insulin sensitivity are compensated by inverse changes in β‐cell responsiveness such that the product of insulin sensitivity and insulin secretion (the disposition index) remains constant. While the disposition index promises to be a useful tool to predict individuals at high risk of developing type 2 diabetes, other factors that contribute to β‐cell dysfunction and mark disease onset and progression include impairments in proinsulin processing and insulin secretion, decreased β‐cell mass and islet amyloid deposition. Emerging data indicate that anti‐diabetic agents, such as the thiazolidinediones that simultaneously target insulin resistance and β‐cell dysfunction, may have a beneficial impact on disease onset and progression. Several landmark clinical studies are underway to investigate if their initial promise is supported by data from large‐scale trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2362.32.s3.5.x

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 301

Metadata

Authors
Bergman, R. N., Finegood, D. T., & Kahn, S. E.
Venue
European Journal of Clinical Investigation
Publisher
Wiley
Published
2002-05-16
Volume
32
Issue
s3
Pages
35-45
ISSN
  • 0014-2972 (ISSN-L)
  • 1365-2362
DOI
10.1046/j.1365-2362.32.s3.5.x
OpenAlex
W1993930772
Cited by
301
References
31
FWCI
12.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.